Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joerg Albrecht

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
JAMA Dermatology|May 2, 2019
Methodology of Evaluating the Laboratory Monitoring of Terbinafine TherapyJoerg Albrecht, Owen N Kramer
International Journal of Dermatology|June 23, 2009
A survey of case reports and case series of therapeutic interventions in the Archives of DermatologyJoerg Albrecht, Alexander Meves, Michael Bigby
Clinical and Experimental Dermatology|January 31, 2025
The recent change in the British National Formulary topical corticosteroid potency classification is not evidence-basedAndrew Affleck, Robert Dawe, Joerg Albrecht
Journal of Clinical Epidemiology|November 18, 2005
Case reports and case series from Lancet had significant impact on medical literatureJoerg Albrecht, Alexander Meves, Michael Bigby
Clinics in Dermatology|December 24, 2023
Sexually transmitted diseases and HIV in transgender patientsAlmog Badash, Dara Grennan, Joerg Albrecht
Journal of the American Academy of Dermatology|April 13, 2019
Comment on "Re-evaluating the need for routine laboratory monitoring on isotretinoin patients: A retrospective analysis"Joerg Albrecht, Owen N Kramer, Michael Bigby
Journal of the American Academy of Dermatology|February 24, 2009
The role of case reports in evidence-based practice, with suggestions for improving their reportingJoerg Albrecht, Victoria P Werth, Michael Bigby
Arthritis and Rheumatism|April 3, 2008
The cutaneous lupus disease activity and severity index as a validated outcome measure for cutaneous lupus erythematosus: comment on the article by Stamm et alMichael Krathen, Joerg Albrecht, Victoria P Werth
Dermatologic Clinics|April 14, 2007
Drug-associated lymphoma and pseudolymphoma: recognition and managementJoerg Albrecht, Lauren Ann Fine, Warren Piette
JAMA Dermatology|February 8, 2023
Double Standards and Inconsistencies in Access to Care-What Constitutes a Cosmetic Treatment?John S Barbieri, Avery LaChance, Joerg Albrecht
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
JAMA Dermatology|May 2, 2019
Methodology of Evaluating the Laboratory Monitoring of Terbinafine TherapyJoerg Albrecht, Owen N Kramer
International Journal of Dermatology|June 23, 2009
A survey of case reports and case series of therapeutic interventions in the Archives of DermatologyJoerg Albrecht, Alexander Meves, Michael Bigby
Clinical and Experimental Dermatology|January 31, 2025
The recent change in the British National Formulary topical corticosteroid potency classification is not evidence-basedAndrew Affleck, Robert Dawe, Joerg Albrecht
Journal of Clinical Epidemiology|November 18, 2005
Case reports and case series from Lancet had significant impact on medical literatureJoerg Albrecht, Alexander Meves, Michael Bigby
Clinics in Dermatology|December 24, 2023
Sexually transmitted diseases and HIV in transgender patientsAlmog Badash, Dara Grennan, Joerg Albrecht
Journal of the American Academy of Dermatology|April 13, 2019
Comment on "Re-evaluating the need for routine laboratory monitoring on isotretinoin patients: A retrospective analysis"Joerg Albrecht, Owen N Kramer, Michael Bigby
Journal of the American Academy of Dermatology|February 24, 2009
The role of case reports in evidence-based practice, with suggestions for improving their reportingJoerg Albrecht, Victoria P Werth, Michael Bigby
Arthritis and Rheumatism|April 3, 2008
The cutaneous lupus disease activity and severity index as a validated outcome measure for cutaneous lupus erythematosus: comment on the article by Stamm et alMichael Krathen, Joerg Albrecht, Victoria P Werth
Dermatologic Clinics|April 14, 2007
Drug-associated lymphoma and pseudolymphoma: recognition and managementJoerg Albrecht, Lauren Ann Fine, Warren Piette
JAMA Dermatology|February 8, 2023
Double Standards and Inconsistencies in Access to Care-What Constitutes a Cosmetic Treatment?John S Barbieri, Avery LaChance, Joerg Albrecht
Pageof 5